Generic Product News (January 2019)
MARKETED BY: ANI Pharmaceuticals, Inc
COMPARE TO: Brethine
INDICATION: ANI Pharmaceuticals launched terbutaline sulfate tablets, the generic equivalent to Brethine, for the prevention and treatment of bronchospasms in asthmatic patients over 12 years who have reversible bronchospasms associated with bronchitis and emphysema. The tablets will be available in 2.5- mg and 5.0-mg doses.
DOSAGE FORM: Tablet
FOR MORE INFORMATION: anipharmaceuticals.com
TESTOSTERONE TOPICAL GEL 1.62%
MARKETED BY: Perrigo Company plc
COMPARE TO: AndroGel topical gelINDICATION: The FDA has approved testosterone topical gel as an AB-rated generic equivalent to AndroGel topical gel. The gel works as a replacement therapy for men with a condition that results in the absence or significant reduction of endogenous testosterone. The gel comes in the following doses: 20.25-mg testosterone/1.25-g packet, 40.5-mg testosterone/2.5-g packet, and 20.25-mg/1.25-g actuation pump.
DOSAGE FORM: Gel
FOR MORE INFORMATION: perrigo.com
ROFLUMILAST TABLETS
MARKETED BY: Breckenridge Pharmaceutical, Inc
COMPARE TO: Daliresp
INDICATION: The FDA has approved roflumilast tablets for the prevention of chronic obstructive pulmonary disease (COPD) exacerbation oSrhafplae re-ups in patients with severe COPD associated with chronic bronchitis and past exacerbations. The newly approved ANI;721 drug is generically equivalent to AstraZeneca’sDaliresp.
DOSAGE FORM: Tablet
FOR MORE INFORMATION: bpirx.com
SOFOSBUVIR 400 MG/VELPATASVIR 100 MG AND LEDIPASVIR 90 MG/SOFOSBUVIR 400 MG
MARKETED BY: Gilead Sciences, Inc
COMPARE TO: Epclusa and Harvoni
INDICATION: Gilead Sciences, announced its plans to launch generic versions of its costly treatments for hepatitis C virus. Sofosbuvir 400 mg/ velpatasvir 100 mg will be generically equivalent to Epclusa, and ledipasvir 90 mg/sofosbuvir 400 mg will be generically equivalent to Harvoni. The drugs are expected to be available by January 2019 at a list price of $24,000, allowing patients to save up to $2500 in out-of-pocket costs per therapy course. The generic launch will expand access to lifesaving drugs.
DOSAGE FORM: Tablet
FOR MORE INFORMATION: gilead.com
